Vocacapsaicin (CAS: 1931116-92-5) is a first-in-class, water-soluble prodrug under development by Concentric Analgesics designed to rapidly release capsaicin upon local administration. It activates TRPV1 receptors, inducing a prolonged refractory state in C-fibers to provide sustained analgesia without impairing sensation, proprioception, or muscle strength. It is being investigated for the management of postoperative pain, demonstrating significant efficacy in reducing pain and opioid consumption for at least 96 hours following a single intraoperative local dose.